Published in J Cell Mol Med on October 23, 2008
Molecular mechanisms of diabetic cardiomyopathy. Diabetologia (2014) 1.53
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res (2009) 1.22
Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta (2014) 1.12
A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol (2012) 1.04
N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1α/HO-1 signaling in diabetic rats. PLoS One (2013) 1.00
N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS One (2011) 0.99
Role of NAD(P)H oxidase in superoxide generation and endothelial dysfunction in Goto-Kakizaki (GK) rats as a model of nonobese NIDDM. PLoS One (2010) 0.94
Novel insights into interactions between mitochondria and xanthine oxidase in acute cardiac volume overload. Free Radic Biol Med (2011) 0.91
Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol (2012) 0.88
Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia (2013) 0.86
Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice. BJU Int (2011) 0.83
Enhanced skeletal muscle expression of extracellular superoxide dismutase mitigates streptozotocin-induced diabetic cardiomyopathy by reducing oxidative stress and aberrant cell signaling. Circ Heart Fail (2014) 0.83
Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol (2014) 0.82
How exercise may amend metabolic disturbances in diabetic cardiomyopathy. Antioxid Redox Signal (2015) 0.80
Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radic Biol Med (2015) 0.80
Normalizing dysfunctional purine metabolism accelerates diabetic wound healing. Wound Repair Regen (2015) 0.79
N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition. BMC Cardiovasc Disord (2015) 0.79
The Role of Oxidative Stress in Myocardial Ischemia and Reperfusion Injury and Remodeling: Revisited. Oxid Med Cell Longev (2016) 0.78
Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats. Acta Pharmacol Sin (2011) 0.78
Finding needles in a haystack: application of network analysis and target enrichment studies for the identification of potential anti-diabetic phytochemicals. PLoS One (2014) 0.75
Diabetic Cardiomyopathy: An Immunometabolic Perspective. Front Endocrinol (Lausanne) (2017) 0.75
High-Intensity Exercise Reduces Cardiac Fibrosis and Hypertrophy but Does Not Restore the Nitroso-Redox Imbalance in Diabetic Cardiomyopathy. Oxid Med Cell Longev (2017) 0.75
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res (2000) 8.62
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov (2007) 5.65
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (2003) 3.19
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev (2007) 3.19
Myocardial cell death in human diabetes. Circ Res (2000) 3.12
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care (2003) 2.74
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension (2000) 2.55
Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2003) 2.26
The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes (2002) 2.20
Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol (2008) 2.15
Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation (2001) 2.07
Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res (2005) 2.05
IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes (2001) 1.92
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem (2005) 1.72
Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res (1999) 1.71
Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes (2002) 1.67
Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J (2004) 1.64
Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol (2005) 1.61
Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci (2005) 1.53
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation (2002) 1.52
Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Invest (2000) 1.51
Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes (2002) 1.48
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes (2007) 1.39
Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol (2006) 1.34
Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia (2006) 1.29
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal (2005) 1.28
Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res (2004) 1.24
Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. Methods Enzymol (2008) 1.23
Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes (2007) 1.20
Diabetic cardiomyopathy. Diabetes Care (1990) 1.11
Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front Biosci (Landmark Ed) (2009) 1.07
Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol (2006) 1.02
Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol (2005) 0.96
Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res (2003) 0.93
Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure. Am J Physiol Heart Circ Physiol (2006) 0.93
Diabetic cardiomyopathy: experimental and clinical observations. N J Med (1994) 0.85
Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J (2005) 0.82
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev (2002) 5.92
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov (2005) 4.61
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Early predictors of outcome in comatose survivors of ventricular fibrillation and non-ventricular fibrillation cardiac arrest treated with hypothermia: a prospective study. Crit Care Med (2008) 3.14
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest (2008) 3.13
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc (2007) 2.84
Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology (2009) 2.83
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A (2009) 2.66
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation (2003) 2.56
Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 2.51
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest. Crit Care Med (2006) 2.48
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes (2002) 2.20
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem (2003) 2.04
The vasodilatory response of skin microcirculation to local heating is subject to desensitization. Microcirculation (2009) 2.02
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes (2004) 2.02
Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology (2012) 2.01
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med (2006) 1.99
Redox regulation of OxyR requires specific disulfide bond formation involving a rapid kinetic reaction path. Nat Struct Mol Biol (2004) 1.99
Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol (2005) 1.98
Clinical profile of pneumonia and its association with rain wetting in patients admitted at a tertiary care institute during pandemic of influenza A (H1N1) pdm09 virus infection. Indian J Chest Dis Allied Sci (2014) 1.97
Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med (2002) 1.97
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol (2008) 1.87
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev (2007) 1.86
Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol (2009) 1.85
Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology (2010) 1.82
Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther (2006) 1.82
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes (2004) 1.79
Body temperature regulation and outcome after cardiac arrest and therapeutic hypothermia. Resuscitation (2011) 1.78
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood (2007) 1.76
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem (2005) 1.72
Cardiac and metabolic effects of hypothermia and inhaled hydrogen sulfide in anesthetized and ventilated mice. Crit Care Med (2010) 1.70
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol (2007) 1.68
Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol (2004) 1.67
Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock (2003) 1.64